Introduction
Achilles tendinopathy, a common orthopaedic condition, has no gold standard non-operative treatment. Pulsed-Electromagnetic Field (PEMF) therapy has been used for various musculoskeletal disorders with promising results. The study is the first to investigate the long-term effects of PEMF therapy for Achilles tendinopathy.
Methods
This double-blinded randomised controlled trial recruited 65 participants at the Chinese University of Hong Kong; and followed them up for 1 year. They were randomly allocated to be treated with active PEMF therapy or sham PEMF therapy for 10 minutes each session, for a total of 16 sessions. The randomisation results were blinded to participants and assessors. Participants reported Achilles tendon pain and its impact on function by the Victorian Institute of Sports Assessment - Achilles (VISA-A) questionnaire and the Numeric Pain Rating Scale (NPRS). The same physiotherapist assessed all outcomes on baseline, 6 and 12 months after commencement of PEMF therapy. An independent sample t-test was used to analyse whether group differences existed at 6 and 12 months.
Results
The participants treated with active PEMF therapy demonstrated significantly improved VISA-A and NPRS scores compared to those receiving sham PEMF therapy. The active PEMF group had significantly higher VISA-A scores than the sham PEMF group at 6 months (p=0.043), but no significant differences were found at 12 months (p=0.793) (figure 01). In addition, NPRS scores were significantly lower in the active PEMF group compared to the Sham group at 6 months (p<0.001) and 12 months (p<0.008) (figure 02). No adverse effects of PEMF therapy were reported during the study period.
Conclusions
PEMF therapy effectively improved rehabilitation outcomes, with statistically significant improvements in pain at 6 months and 1 year. There was also a quicker regain of function at 6 months compared to the sham group. Future research should investigate the optimal dosage of PEMF and its effect as a combined multi-modal treatment regime for patients with Achilles tendinopathy.